Drug developer Pfizer Inc. said that it named George A. Lorch as its new chairman of the board of directors, one week following the abrupt resignation of CEO Jeffrey B. Kindler.
Sigma Life Science announced that its SAGE Labs initiative has successfully used its proprietary CompoZr Zinc Finger Nuclease technology to generate knock-in rats in which foreign genes have been inserted.
JM Science announces their AQUACOUNTER Karl Fischer Volumetric Titrator. This high-end titrator has a very wide range from 100 ppm to 100% water content with is maximum capability for automation and future up-gradability.
For the first time, scientists have created functioning human intestinal tissue in the laboratory from pluripotent stem cells. Researchers say their findings will open the door to unprecedented studies of human intestinal development, function and disease.
A team led by Massachusetts General Hospital researchers has developed a faster way to engineer synthetic enzymes that target specific DNA sequences for inactivation, repair or alteration.
MorphoSys AG announced the signing of a non-exclusive license and technology transfer agreement between its subsidiary Sloning BioTechnology GmbH and Pfizer. The agreement covers the installation, training and use of Sloning's technology platform Slonomics.
Merck KGaA announced that Dr. Stefan Oschmann will become a member of the Executive Board and General Partner of Merck KGaA. Dr. Kai Beckmann will become a member of the Executive Board and General Partner of Merck KGaA effective April 1, 2011.
Amgen announced results from new analyses comparing XGEVA (denosumab), the first new treatment for advanced cancer patients with bone metastases in nearly a decade to prevent skeletal-related events, to Zometa (zoledronic acid).
ImmunoGen, Inc., a biopharmaceutical company that develops anticancer therapeutics using its Targeted Antibody Payload technology, presented the first clinical data for trastuzumab-DM1 used in combination with pertuzumab for HER2+ metastatic breast cancer.
Valeant Pharmaceuticals International Inc. said that Chairman Bill Wells resigned from the board to pursue other interests. The change comes as Valeant deals with setbacks for two of its most advanced drug candidates.
French pharmaceutical group Sanofi-Aventis said it has extended its unsolicited $18.5 billion takeover offer for U.S.-based biotech company Genzyme.
PharmaNet Development Group, Inc. is launching two technology platforms—Initiator and PKS—that will provide improvements in clinical study timelines by accelerating data acquisition and the processing of final client reports in its Phase 1 clinics.
Tecan has launched a gas control module for its Infinite 200 PRO multimode microplate reader, creating one of the most comprehensive solutions on the market for cell-based assays.
Taconic and Transposagen Biopharmaceuticals have entered into a non-exclusive marketing and distribution agreement for Taconic to produce and distribute Transposagen’s FatRat.
WIL Research Company, Inc., a global Contract Research Organization and leading provider of drug development services, appointed Howard Moody as chief information officer and Alan Findlater as chief commercial officer.